- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- No more ‘old school’: How Duke Health is reimagining workforce development
- Why private practice dentistry needs a better model
- Chief nurses: Hospital finances improve with nursing investments
- Mississippi health system goes ‘all in’ on Epic with $115M investment
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Ascension Wisconsin CEO to step down
- The hospitals, health systems cutting jobs in 2026
- Nonprofit highlights rural opioid care strategies
- The 7 things on the table in the Mount Sinai-Anthem negotiations
- Wearables data predicts patient engagement: Mayo Clinic study
- Advocate plans largest US hospital drone delivery network
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- Indiana system opens $21.7M outpatient center
- Trump administration targets medical school admissions: 4 notes
- EyeSouth Partners continues 2026 expansion with Louisiana practice
- RSV lingers in parts of US even as flu and COVID-19 recede
- A huge month for CMS policy
- What the Health? From KFF Health News: A Headless CDC
- GI is exploding with new tech—but how do patients feel about it?
- Maryland physician to pay $500K+ to settle false claims allegations
- Rhode Island oral surgeon launches Congressional campaign
- Premier Anesthesia, City of Hope Phoenix ink partnership
- 20 behavioral health leaders challenge industry assumptions
- What simulation training revealed about GI skills gaps
- Judge dismisses physician’s wrongful termination suit against staffing firm
- 3 California behavioral health centers to close amid funding shifts
- North Carolina practice to close after 40+ years
- St. Tammany opens outpatient cardiology center
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- 6 dental practice openings to know
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- APRNs, PAs account for most antipsychotic prescriptions for Medicare Part D: Study
- Infosys to acquire Optimum Healthcare IT in $465M deal
- Oklahoma House passes bill expanding scope of dental assistants
- Dr. Nellie Kim-Weroha joins American Association of Orthodontists’ Board of Trustees
- California behavioral health agency to close 2 centers
- 52 DSOs to know: 2026
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- California peer-run behavioral health center to close amid funding shift
- Remarks at the Financial Stability Oversight Council Meeting
- ‘Integration only works if data lives in the same system’: How 5 systems are operationalizing behavioral health
- Inside UHS’ playbook for responsible behavioral health growth
- Epic4 Specialty Partners adds Illinois practice
- The unsolved problems still plaguing dentistry
- American Dental Association adds mental health, GLP-1 prompts to patient forms
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
- Cologuard campaign reunites ‘Full House’ stars to give ‘The Talk’ about colon cancer screening
- Lilly to remove certain insulin products from European markets by 2027
- Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis
- Study Warns Fluoride Bans May Raise Tooth Decay in Children
- WuXi Bio's record number of new projects in 2025 leaned heavily on US clients
- “Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
- Gilead inks Manta pact to dive deeper into cancer patient support
- Cheap Children's Clothing Tainted With Lead, Study Says
- Insulin Prices Fell For Medicare Patients Under Biden-Era Caps, Study Finds
- New Fathers Face Mental Health Challenges, Study Finds
- Your Choice Of Booze Influences Your Risk Of Death, Study Says
- AI Gets a 'D' When Judging Scientific, Medical Claims
- New Online Tool Helps Parkinson's Patients Weigh Brain Implant Decision
- AI chatbot use for health information up 16% from 2024: Rock Health survey
- ‘They Tricked Me’: A Father Was Chained After He Went to ICE To Reunite With His Kids
- Wilmington PharmaTech commits $50M to US API expansion
- Strides recalls nearly 90K bottles of children's ibuprofen after contamination complaints
- Trump administration unveils national policy framework for AI as it moves to override state laws
- Breast Cancer Locator System Submitted for De Novo 510(k) by Cairn Surgical
- Breast Cancer Locator System Submitted for De Novo 510(k) by Cairn Surgical
- 17 spine surgery firsts in Q1
- 17 spine surgery firsts in Q1
- Cencora acquiring EyeSouth Partners' retina business for $1.1B
- A look at how Optum Rx is using AI to address pharmacy fraud, waste and abuse
- Nursing Homes Accused of False Diagnoses To Hide Drug Use
- FDA Approves Higher-Dose Wegovy To Help People Lose More Weight
- Teens Often Pressured To Send Sexual Photos by Someone They Know, Study Finds
- Nearly 90,000 Bottles of Children’s Ibuprofen Recalled Nationwide
- Rural Residents Have Highest Cancer Death Rates, Researchers Say
- Your Bank Account Might Show How Well Your Brain Will Age, Researchers Say
The Trump Administration is developing a web site named TrumpRx.com. Only a lander is up right now at that URL, but the web site will eventually direct Americans to sources for pharmaceuticals whose prices have been lowered by Most Favored Nation (MFN) agreements:
https://thehill.com/homenews/5529456-trumprx-online-platform-drugs/
White House launching TrumpRx.com for lower-priced drugs: What to know
By Joseph Choi - September 30, 2025The Trump administration on Tuesday announced plans to launch TrumpRx.com, an online platform that it says will direct Americans to lower-priced drugs.
The announcement came one day after President Trump’s deadline for drugmakers to comply with his “Most Favored Nation” (MFN) executive order, which included a mandate for companies to establish direct-to-consumer for medicines, cutting out middlemen.
Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid Services, said on Tuesday that drugs would be made available through the platform “often at full MFN, and always at lower prices than currently available. This is bypassing middlemen. It increases transparency, and many instances, prices are 80 percent lower than they are today.”
A senior administration official said it hoped to launch the website early next year, in a briefing Tuesday.
“To be clear, the government is not getting into the drug distribution business. Rather, this is a convening site where Americans can come and know that this is a place where they can go direct-to-consumer and access the lowest prices available through the President’s MFN initiative,” they added.
How the site will be constructed and other finer details are still being worked out, according to the official.
Asked whether patients will be able to use their insurance to purchase drugs through TrumpRx.com, a senior administration official did not directly answer, noting instead that pharmaceutical manufacturers are often public companies with fiduciary responsibilities to their shareholders as well as other “obscures priorities.”
The move echoes on that the pharmaceutical industry launched just the day before, with the trade group PhRMA launching AmericasMedicines.com on Monday, gathering different drugmakers that currently offer direct-to-consumer programs.
TrumpRx.gov is now up and running:
Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients
The White House
February 5, 2026HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced the launch of TrumpRx.gov. Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).
- Today’s launch features drugs made by the first five manufacturers to reach MFN pricing deals with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
- Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months.
- TrumpRx.gov provides patients with access to a world-class experience for accessing deep discounts on the medicines they need. Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov.
DELIVERING LOWER COSTS ON THE MOST POPULAR DRUGS: As of today, patients purchasing directly through TrumpRx.gov will be able to see massive price reductions on 40 of the most popular and expensive branded medicines in the nation. Select examples include:
- Historic price reductions for Americans on the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
- The monthly prices of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $350 and as low as $199, depending on dosage strength.The monthly price of the Wegovy pill will fall from $1,349 to as low as $149, depending on dosage strength.
- The monthly price of Zepbound and will fall from $1,088 to an average price of $346 and as low as $299, depending on dosage strength.
- Massive savings on some of the most commonly used fertility medications in the country to help families grow. Many patients struggling with infertility pay for their medicines out-of-pocket, meaning they will stand to save more than $2,000 per cycle of fertility drugs, on average.
- Gonal-F, one of the most commonly-used fertility drugs, will see its price reduced to as low as $168 per pen, depending on dosage strength.
- The price of Cetrotide, another commonly used fertility medicine, will drop from $316 to $22.50.
- The price of Ovidrel will fall from $251 to $84.
- Discounts on numerous other high-cost drugs, including:
- Bevespi Aerosphere, an inhaler used to treat chronic obstructive pulmonary disease (COPD), will be discounted from $458 to $51.
- Airsupra, an inhaler used to treat asthma symptoms and attacks, will see a price drop from $504 to $201.
- Eucrisa, a topical ointment for atopic dermatitis, will be discounted from $792 to $158.
- Insulin Lispro will be available for as low as $25 per month.
- Duavee, a medication used to treat hot flashes and osteoporosis, will see its price cut from $202 to $30.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 16 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure that they pay their fair share for innovative medicines.
- On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan, which would lower drug prices by codifying the savings from his Most-Favored-Nation pricing initiative, lower insurance premiums, hold insurance companies accountable, and maximize price transparency.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.


















